

- **Name:** Michael Lim
- **Current Position & Affiliation:** Stanford University
- **Country:** USA

• **Educational Background:**

Undergraduate 1995: B.S., Biochemistry, University of New Hampshire, Durham, NH
 Doctoral/Graduate 2000: M.D., The Johns Hopkins University School of Medicine, Baltimore, MD
 Postdoctoral 2000 – 2001: Intern, General Surgery, Stanford University Medical Center, Stanford, CA
 2001 – 2007: Resident, Neurosurgery, Stanford University Medical Center, Stanford, CA

• **Professional Experience:**

2007 – 2013: Assistant Professor of Neurosurgery, Oncology, and Radiation Oncology and Radiation Molecular Sciences, The Johns Hopkins University School of Medicine
 2013 – 2017: Associate Professor of Neurosurgery, Oncology, and Radiation Oncology and Radiation Molecular Sciences, The Johns Hopkins University School of Medicine
 2017 – 2020: Professor of Neurosurgery, Oncology, Otolaryngology, and Radiation Oncology and Radiation Molecular Sciences, The Johns Hopkins University School of Medicine
 2020 – Present: Adjunct Professor of Neurosurgery, The Johns Hopkins University School of Medicine, Professor and Chair of Neurosurgery, and by courtesy, Oncology, Otolaryngology Radiation Oncology and Neurology, Stanford University School of Medicine

• **Professional Organizations:**

2007 - Present Congress of Neurological Surgeons (CNS)
 2007 - Present American Association of Neurological Surgeons (AANS)
 2007 - Present Society for Neuro-Oncology (SNO)
 2008 - Present American Society for Clinical Oncology (ASCO)
 2021 - Present American Academy of Neurological Surgery
 2021 - Present Society for Neurological Surgery

• **Main Scientific Publications:**

1. Singh K, Railton C, Hotchkiss K, Herndon J, Peters K, Friedman H, Desjardins A, Ashley D, Johnson MO, Patel A, Friedman A, Lim M, Fecci P, Piccioni D, McGranahan T, Nagpa S, Sulman E, Mischel P, Khasraw. RTID-07. A Randomized Window of Opportunity Trial with Dose Escalation to Evaluate Fluoxetine and Temozolomide in Glioma, Neuro-Oncology, 25 (2023) v260-v260
2. Smith E, Naik A, Goel M, Wen P, Lim M, Chang S, Germano I, QLTI-12. Adult Neuro-Oncology Trial Landscape in the United States Over Five Decades. Neuro-Oncology, 25 (2023) v247-v247
3. Kleinberg L, Ye X, Sharfman W, Jackson C, Redmond K, Bettgowda C, Szajna K, Isennoek W, Wollett J, Lipson E, Lim M. CTIM-03. Long Term Follow-Up of a Prospective Safety and Toxicity Study of

Immune Checkpoint Inhibitor Therapy Initiated 8 Days Prior to Radiosurgery for Melanoma Brain or Spine Metastasis. *Neuro-Oncology*, 25 (2023) v61-v61

4. Wu C, Chen Y, Lin Y, Wei, KC Chang K, Feng L, Wu A, Chen K, Ren A, Nitta R, Wu, A, Pant A, Cho K,

Mackall C, Chuang J, Huang CY, Li G, Jackson C, Chen PY, Lim M. TMIC-38. Mitochondrial ATP Biogenesis Regulated by VDAC1 in TMEM119+ Tumor-Associated Microglia and Macrophages Mediates High-Grade Glioma Growth. *Neuro-Oncology*, 25 (2023) v286-v286

5. Wen P, Alexander B, Berry D, Buxton M, Cavenee W, Colman H, de Groot J, Ellingson B, Gordon G, Hyddmark E, Khasraw M, Lim M, Mellinghoff I, Mikkelsen T, Perry J, Powell A, Sulman E, Tanner K, Weller M, Yung WKA, Blondin N, Brenner A, Butt O, de la Fuente M, Drappatz J, Iwamoto F, Kim L, Lee E, Mantica M, Nabors B, Newton H, Schiff D, Walbert T, Weathers SP, Cloughesy T, Lassman A. CTNI-85. GBM Agile Platform Trial for Newly Diagnosed and Recurrent GBM: Results of First Experimental Arm, REGORAFENIB. *Neuro-Oncology*, 25 (2023) v97-v98

6. De Groot, J, Cloughesy, T, Berry DA, Buxton, M, Colman, H, Ellingson, BM, Gordon, GB, Lassman, AB, Lim, M, Mellinghoff, IK, Sulman, EP, Weller, M, Wen, PY, Hyddmark, E, Mikkelsen, T, Owen, S, Mason, WP, Drappatz, J, Blondin, N, Perry, JR, Agile Investigators. Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma. LIPPINCOTT WILLIAMS & WILKINS. 2024

7. Tran A, Choi J, Bergsneider B, Kim L, Schonfeld E, Abikenari M, Verma R, Bog Cho K, Lim M. TMIC

32. Infigratinib Inhibition of the THBS1 Pathway in Melanoma Brain Metastasis. *Neuro-Oncology*, Volume 26, Issue Supplement_8, November 2024, Page viii305, <https://doi.org/10.1093/neuonc/noae165.1210>

MICHAEL LIM, M.D.

31

Curriculum Vitae

8. Kim L, Choi J, Nitta R, Pant A, Schonfeld E, Li G, Jackson C, Wang X, Lim M, IMMU-33.

Reprogramming of Myeloid Cell Metabolism via Heme Oxygenase-1 Inhibition Potentiates Anti-Tumor Immunity in a Murine Glioma Model. *Neuro-Oncology*, Volume 26, Issue Su